Mifepristone Dosing Optimization via Serum Feedback Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Administration of the same dose of mifepristone results in widely varying blood serum levels among patients, leading to inconsistent treatment efficacy, with levels differing by up to 800% between individuals, potentially rendering the treatment ineffective for some patients.
Innovation Solution
A method involving the administration of seven or more daily doses of mifepristone over seven or more days, followed by serum level testing to adjust the daily dose to achieve blood levels greater than 1300 ng/mL, using a plasma sampling collection device for accurate detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If the same dose of mifepristone is administered to different patients, then the treatment can be standardized and easy to implement, but the blood serum levels vary widely (up to 800% difference) resulting in inconsistent treatment efficacy
Solution Approach 1:
The patent changes the dosing parameter from a fixed standardized dose to an adjusted dose based on measured blood serum levels. Patients receive initial dosing followed by level measurement, then dose adjustment to achieve target therapeutic levels, transforming a one-size-fits-approach to a personalized dosing regimen that accounts for individual metabolic variations
Solution Approach 2:
The patent implements a feedback loop where blood serum levels of mifepristone are measured after initial dosing, and this measurement information is used to adjust subsequent doses. This closed-loop control ensures that each patient's treatment is optimized based on their actual drug levels, improving reliability while maintaining operational feasibility
2Reliability
If the daily dose of mifepristone is increased to ensure therapeutic levels, then treatment efficacy is improved, but the risk of exceeding safe levels and causing adverse effects increases
Solution Approach 1:
The patent uses blood serum level measurements as feedback to control dosing, allowing clinicians to see exactly where each patient stands relative to the therapeutic window. This enables precise dose adjustments that push patients into the therapeutic range without overshooting into toxic levels, as the measured levels guide each dosing decision
Solution Approach 2:
The patent transforms static fixed dosing into a dynamic adjusted dosing regimen. The dose is not fixed but is adjusted based on measured blood levels, allowing the treatment to adapt to each patient's unique pharmacokinetics. This dynamic approach enables safer escalation to effective doses while monitoring to prevent excessive accumulation
3Reliability
If individualized dosing based on blood level measurement is implemented, then treatment efficacy is optimized, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent performs blood level measurement after an initial dosing period before final dose determination. This preliminary action provides the necessary information to make informed dosing decisions, breaking down the complex individualized dosing into manageable stages: initial dosing, measurement, then adjustment based on results
Solution Approach 2:
The patent divides the dosing protocol into discrete segments: an initial dosing phase followed by a measurement phase, then an adjusted dosing phase. This segmentation makes the complex individualized approach more manageable by breaking it into distinct, sequential steps rather than a single complex decision
Data Source
AI summary
The present invention provides a method for optimizing levels of mifepristone in a patient suffering from a mental disorder amenable to treatment by mifepristone. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1300 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1300 ng/mL.